{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:16:01Z","timestamp":1791515761821,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR001879"],"award-info":[{"award-number":["KL2TR001879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL0439"],"award-info":[{"award-number":["T32HL0439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["370C-20220066"],"award-info":[{"award-number":["370C-20220066"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010411","name":"Een H\u00e4erz fir kriibskrank Kanner","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008471","name":"Fondation Gustave et Simone Pr\u00e9vot","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA283759"],"award-info":[{"award-number":["U54CA283759"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["I01BX000918"],"award-info":[{"award-number":["I01BX000918"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011017","name":"Recherches Scientifiques Luxembourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011691","name":"Fondation\u00a0Recherche Cancer et Sang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.218011","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:04:22Z","timestamp":1756742662000},"page":"218011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia"],"prefix":"10.1016","volume":"633","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9274-1424","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Pottier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-9925","authenticated-orcid":false,"given":"Francesca","family":"Liccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lorant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-9538","authenticated-orcid":false,"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-9648","authenticated-orcid":false,"given":"Davide","family":"Brusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-607X","authenticated-orcid":false,"given":"Sergio","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-2382","authenticated-orcid":false,"given":"Antonello","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Skuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Boettcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-8176","authenticated-orcid":false,"given":"Claudia","family":"Cerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-3779","authenticated-orcid":false,"given":"Franck","family":"Morceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-4725","authenticated-orcid":false,"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.canlet.2025.218011_bib1","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.canlet.2025.218011_bib2","first-page":"5762","article-title":"Therapeutic opportunities in cancer therapy: targeting the p53-MDM2\/MDMX interactions","volume":"11","author":"Munisamy","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog."},{"key":"10.1016\/j.canlet.2025.218011_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109508","article-title":"CDK9 inhibitors reactivate p53 by downregulating iASPP","volume":"67","author":"Wu","year":"2020","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010098","article-title":"Antitumor effects of PRIMA-1 and PRIMA-1(Met) (APR246) in hematological malignancies: still a mutant P53-dependent affair?","volume":"10","author":"Menichini","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1223","article-title":"Rapid degradation of histone deacetylase 1 (HDAC1) reveals essential roles in both gene repression and active transcription","volume":"53","author":"English","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.218011_bib7","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2025.218011_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217526","article-title":"Temporal myc dynamics permit mitotic bypass, promoting polyploid phenotypes","volume":"613","author":"Loycano","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00210-024-03599-2","article-title":"Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment","volume":"398","author":"Baghel","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1535-7163.MCT-09-1071","article-title":"AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples","volume":"9","author":"Squires","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2021005872","article-title":"Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study","volume":"6","author":"Gregory","year":"2022","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.canlet.2025.218011_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.canlet.2025.218011_bib13","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/blood-2022-160277","article-title":"The multi-CDK inhibitor dinaciclib shows synergistic activity with the BET inhibitor PLX51107 and reverses BET resistance through inhibition of canonical wnt signaling in acute myeloid leukemia (AML)","volume":"140","author":"Marr","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2025.218011_bib14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","article-title":"Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia","volume":"108","author":"Pariury","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus Endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218011_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus Fulvestrant on overall survival in Hormone receptor-positive, ERBB2-negative breast cancer that progressed on Endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2025.218011_bib18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and Fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.218011_bib19","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.21873\/anticanres.15416","article-title":"The novel, Orally Bioavailable CDK9 inhibitor atuveciclib sensitises Pancreatic cancer cells to TRAIL-induced cell death","volume":"41","author":"Ruff","year":"2021","journal-title":"Anticancer Res."},{"issue":"13","key":"10.1016\/j.canlet.2025.218011_bib20","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1080\/07391102.2016.1231084","article-title":"Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations","volume":"35","author":"Sixto-Lopez","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41375-023-02076-8","article-title":"ATP1A1\/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides","volume":"38","author":"Cerella","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.canlet.2025.218011_bib22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/cac2.12590","article-title":"Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy","volume":"44","author":"Schnekenburger","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"10.1016\/j.canlet.2025.218011_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","article-title":"Mubritinib targets the electron Transport Chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia","volume":"36","author":"Baccelli","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","article-title":"Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes","volume":"54","author":"Ehx","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.canlet.2025.218011_bib26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41375-018-0069-1","article-title":"Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin","volume":"32","author":"Lavallee","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2025.218011_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.36","article-title":"Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets","volume":"6","author":"Maiga","year":"2016","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.canlet.2025.218011_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-018-0103-6","article-title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","volume":"8","author":"Marquis","year":"2018","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.canlet.2025.218011_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","article-title":"Quantitative proteomics of the cancer cell line Encyclopedia","volume":"180","author":"Nusinow","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib30","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1038\/s41467-025-62005-4","article-title":"Epigenomic diagnosis and prognosis of acute myeloid leukemia","volume":"16","author":"Marchi","year":"2025","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.canlet.2025.218011_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.canlet.2025.218011_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) Older\/Unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.canlet.2025.218011_bib33","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the Anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218011_bib34","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.218011_bib35","article-title":"AML-484 first results of a phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.canlet.2025.218011_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and Biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a Nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.canlet.2025.218011_bib37","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.218011_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.canlet.2025.218011_bib39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41416-021-01561-0","article-title":"APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation","volume":"125","author":"Kobayashi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.218011_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.218011_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1576781","article-title":"Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation","volume":"15","author":"Tian","year":"2025","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.218011_bib42","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and Antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2025.218011_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101475","article-title":"The role of the cyclin dependent kinase inhibitor p21(cip1\/waf1) in targeting cancer: molecular mechanisms and novel therapeutics","volume":"11","author":"Al Bitar","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.canlet.2025.218011_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.61","article-title":"Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression","volume":"4","author":"Sachweh","year":"2013","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.canlet.2025.218011_bib45","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2013.856007","article-title":"The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan","volume":"55","author":"Song","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.canlet.2025.218011_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.canlet.2025.218011_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.218011_bib48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/genes10030244","article-title":"MYC oncogene contributions to release of cell cycle brakes","volume":"10","author":"Garcia-Gutierrez","year":"2019","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.canlet.2025.218011_bib49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Cancer"},{"issue":"17","key":"10.1016\/j.canlet.2025.218011_bib50","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-Aminopyridine-based and 2-Aminopyrimidine-based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory Solid tumors and hematological malignancies","volume":"67","author":"Saidahmatov","year":"2024","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.canlet.2025.218011_bib51","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1128\/MCB.25.23.10220-10234.2005","article-title":"Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription","volume":"25","author":"Faiola","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.canlet.2025.218011_bib52","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"19\u201320","key":"10.1016\/j.canlet.2025.218011_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1101\/gad.350736.123","article-title":"MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival","volume":"37","author":"Hurd","year":"2023","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2016.05.077","article-title":"Irreversible APC(Cdh1) inactivation underlies the point of No return for cell-cycle entry","volume":"166","author":"Cappell","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.canlet.2025.218011_bib56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molcel.2019.08.020","article-title":"Transient hysteresis in CDK4\/6 activity underlies passage of the restriction point in G1","volume":"76","author":"Chung","year":"2019","journal-title":"Mol. Cell"},{"issue":"7672","key":"10.1016\/j.canlet.2025.218011_bib57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature23880","article-title":"Competing memories of mitogen and p53 signalling control cell-cycle entry","volume":"549","author":"Yang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.218011_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123259","article-title":"A review on cyclin-dependent kinase 5: an emerging drug target for neurodegenerative diseases","volume":"230","author":"Batra","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2025.218011_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117147","article-title":"Posttranslational modifications of E2F family members in the physiological state and in cancer: roles, mechanisms and therapeutic targets","volume":"178","author":"Sun","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.canlet.2025.218011_bib61","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/0008-5472.CAN-06-3985","article-title":"Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation","volume":"67","author":"Stiehl","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218011_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116130","article-title":"Protein lysine acetyltransferase CBP\/p300: a promising target for small molecules in cancer treatment","volume":"171","author":"Gou","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.canlet.2025.218011_bib63","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hernandez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2025.218011_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101140","article-title":"Sialylated IgG-activated integrin beta4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis","volume":"61","author":"Chen","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2025.218011_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216121","article-title":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","volume":"559","author":"Moran","year":"2023","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.canlet.2025.218011_bib66","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.canlet.2025.218011_bib67","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1074\/jbc.M113.517599","article-title":"Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo","volume":"289","author":"Glauben","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.canlet.2025.218011_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005782","article-title":"Histone deacetylase inhibitors enhance CD4 T cell susceptibility to NK cell killing but reduce NK cell function","volume":"12","author":"Pace","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2025.218011_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2020.06.003","article-title":"AML chemoresistance: the role of mutant TP53 subclonal expansion and therapy strategy","volume":"87","author":"Yan","year":"2020","journal-title":"Exp. Hematol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:03:13Z","timestamp":1772830993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":69,"alternative-id":["S0304383525005816"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218011","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218011"}}